Correlation Between Assembly Biosciences and Connect Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Assembly Biosciences and Connect Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Assembly Biosciences and Connect Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Assembly Biosciences and Connect Biopharma Holdings, you can compare the effects of market volatilities on Assembly Biosciences and Connect Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Assembly Biosciences with a short position of Connect Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Assembly Biosciences and Connect Biopharma.

Diversification Opportunities for Assembly Biosciences and Connect Biopharma

-0.02
  Correlation Coefficient

Good diversification

The 3 months correlation between Assembly and Connect is -0.02. Overlapping area represents the amount of risk that can be diversified away by holding Assembly Biosciences and Connect Biopharma Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Connect Biopharma and Assembly Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Assembly Biosciences are associated (or correlated) with Connect Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Connect Biopharma has no effect on the direction of Assembly Biosciences i.e., Assembly Biosciences and Connect Biopharma go up and down completely randomly.

Pair Corralation between Assembly Biosciences and Connect Biopharma

Given the investment horizon of 90 days Assembly Biosciences is expected to generate 0.59 times more return on investment than Connect Biopharma. However, Assembly Biosciences is 1.69 times less risky than Connect Biopharma. It trades about -0.17 of its potential returns per unit of risk. Connect Biopharma Holdings is currently generating about -0.21 per unit of risk. If you would invest  1,680  in Assembly Biosciences on August 27, 2024 and sell it today you would lose (176.00) from holding Assembly Biosciences or give up 10.48% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Assembly Biosciences  vs.  Connect Biopharma Holdings

 Performance 
       Timeline  
Assembly Biosciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Assembly Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong primary indicators, Assembly Biosciences is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.
Connect Biopharma 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Connect Biopharma Holdings are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Connect Biopharma sustained solid returns over the last few months and may actually be approaching a breakup point.

Assembly Biosciences and Connect Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Assembly Biosciences and Connect Biopharma

The main advantage of trading using opposite Assembly Biosciences and Connect Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Assembly Biosciences position performs unexpectedly, Connect Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Connect Biopharma will offset losses from the drop in Connect Biopharma's long position.
The idea behind Assembly Biosciences and Connect Biopharma Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Other Complementary Tools

Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Transaction History
View history of all your transactions and understand their impact on performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments